Death in Alpine's Keytruda combo trial triggers clinical hold, raises specter of earlier tragedy

A patient has died in a clinical trial that is testing Alpine Immune Sciences’ davoceticept in combination with Merck’s Keytruda. The death in the study of adults with advanced malignancies triggered a partial clinical hold—and raised the specter of an earlier tragedy.